Alpha Tau Medical’s (DRTS) Buy Rating Reiterated at HC Wainwright

by · The Markets Daily

HC Wainwright reiterated their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS – Free Report) in a report released on Tuesday morning, Marketbeat reports. HC Wainwright currently has a $16.00 target price on the stock.

DRTS has been the subject of a number of other research reports. Benchmark reaffirmed a “buy” rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Thursday, October 15th. Barclays upped their price target on Alpha Tau Medical from $17.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, September 3rd. Finally, Zacks Research lowered shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a report on Tuesday, September 1st. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $15.40.

Get Our Latest Research Report on DRTS

Alpha Tau Medical Stock Down 4.3%

DRTS opened at $12.90 on Tuesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.79 and a current ratio of 11.09. Alpha Tau Medical has a fifty-two week low of $3.43 and a fifty-two week high of $15.79. The firm’s fifty day moving average is $14.41 and its 200 day moving average is $11.86. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -12.40 and a beta of 1.22.

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.36). On average, sell-side analysts forecast that Alpha Tau Medical will post -1.05 earnings per share for the current fiscal year.

Insider Buying and Selling at Alpha Tau Medical

In related news, CFO Raphi Levy sold 17,730 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $14.00, for a total value of $248,220.00. Following the sale, the chief financial officer owned 90,180 shares in the company, valued at approximately $1,262,520. The trade was a 16.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 39.50% of the company’s stock.

Hedge Funds Weigh In On Alpha Tau Medical

Several institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC bought a new stake in shares of Alpha Tau Medical in the 1st quarter worth about $286,000. Principal Financial Group Inc. purchased a new stake in shares of Alpha Tau Medical during the 1st quarter valued at about $132,000. Finally, Everhart Financial Group Inc. purchased a new stake in shares of Alpha Tau Medical during the 2nd quarter valued at about $126,000. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

(Get Free Report)

Alpha Tau Medical Ltd. is an Israel-based medical technology company developing targeted radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver highly localized alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses tiny radioactive sources, including radium-224, that are placed in or near a tumor. The sources generate short-range alpha-emitting atoms that diffuse through the tumor and damage cancer cells.

See Also